Allurion announces partnership with Bionut to offer discounted Mounjaro

Allurion Technologies (ALUR) announced a partnership with Bionut to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. Previously reported results have shown that the combination of the Allurion Smart Capsule with low doses of tirzepatide can significantly enhance outcomes. In 76 patients treated with the Allurion Smart Capsule and started on low-dose tirzepatide after completing their first 45 days of balloon therapy, the average total body weight loss at 12 months was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. No patients discontinued early, and all patients remained adherent to tirzepatide for the duration of the study. Importantly, only low doses of tirzepatide were used in the study. Allurion is exploring similar partnerships in other regions to increase the accessibility of GLP-1s for use in combination therapy.